CIK 0001867096 · Large accelerated filer
Xeris Biopharma Holdings, Inc.
Sign in to watch- Ticker
- XERS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 871082097
- Phone
- 844-445-5704
- Business address
- 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,678,894
- in 11 filings, $1.7M under 10b5-1 plans
Net −$1,678,894. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award | +193,333 | 263,829 | ||
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award · Stock Option (Right to Buy) | +160,335 | 160,335 | ||
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award · Stock Option (Right to Buy) | +25,136 | 25,136 | ||
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award · Stock Option (Right to Buy) | +28,072 | 28,072 | ||
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award · Stock Option (Right to Buy) | +34,977 | 34,977 | ||
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2021-10-05 | Shannon John Patrick Jr See Remarks | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award | +384,780 | 384,780 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award | +110,000 | 494,780 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +11,228 | 11,228 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +28,072 | 28,072 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +11,266 | 11,266 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +14,036 | 14,036 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2021-10-05 | PRESTRELSKI STEVEN Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2021-10-05 | PERSKY MARLA Director | Grant or award · Stock Option (Right to Buy) | +19,650 | 19,650 | ||
| 2021-10-05 | PERSKY MARLA Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-10-05 | PERSKY MARLA Director | Grant or award · Stock Option (Right to Buy) | +11,228 | 11,228 | ||
| 2021-10-05 | PERSKY MARLA Director | Grant or award · Stock Option (Right to Buy) | +11,228 | 11,228 | ||
| 2021-10-05 | Pieper Steven Chief Financial Officer | Grant or award | +23,775 | 23,775 |
Page 16 of 18 · 354 trades